Efficacy and Safety of Long-Term Insulin Pump Treatment in Patients With Type 1 Diabetes Aged Over 50 Years
| Autor: | Bartłomiej Matejko, Tomasz Klupa, M. T. Malecki, Beata Kieć-Wilk, Sabina Krzyżowska |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
Blood Glucose
Male Insulin pump medicine.medical_specialty endocrine system diseases Endocrinology Diabetes and Metabolism medicine.medical_treatment 030209 endocrinology & metabolism 03 medical and health sciences Insulin Infusion Systems 0302 clinical medicine Endocrinology Internal medicine medicine Humans Hypoglycemic Agents Insulin Effective treatment In patient Aged Retrospective Studies Aged 80 and over Glycated Hemoglobin Type 1 diabetes business.industry nutritional and metabolic diseases Retrospective cohort study Middle Aged medicine.disease Hypoglycemia Diabetes Mellitus Type 1 Treatment Outcome 030220 oncology & carcinogenesis Autoimmune diabetes Cohort Female business |
| Zdroj: | Web of Science |
| Popis: | Continuous subcutaneous insulin infusion (CSII) therapy using insulin pumps has become widely used in the treatment of type 1 diabetes mellitus (T1DM). This retrospective study aimed to assess the efficacy and safety of long-term insulin pump treatment in patients with T1DM aged ≥50 years. The study included patients aged ≥50 years, who had a diagnosis of T1DM based on clinical criteria and/or presence of autoantibodies characteristic of autoimmune diabetes, and had received ≥5 years of recent and uninterrupted treatment with a personal insulin pump. We analyzed records on HbA1c levels across the entire observation period. The cohort comprised 17 patients, of whom 6 (35%) were men and 11 (65%) were women. The mean duration of observation was 6.6 years, during which patients had a mean of 8.4 HbA1c measurements. Mean HbA1c level over the entire observation period was 6.7% (range, 5.3-7.4%). Overall, 11 patients (65%) had mean HbA1c levels at the ADA-recommended target of |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|